Governments around the world have been stockpiling Roche's Tamiflu to protect their citizens in the event of a flu pandemic--a practice that has been questioned by critics who say there's not enough evidence the drug works. Now, Roche has fresh data showing Tamiflu saved lives during the H1N1 swine flu outbreak of 2009.
A British pound rising against the dollar cut into results at Smiths Group--but its U.S.-based Smiths Medical division, beset by competitors, led the bad-news story in the company's earnings report on the first half of its 2014 fiscal year.
With Augmedix's new $3.2 million in venture funding, the use of Google Glass for healthcare gets a major boost. The San Francisco startup uses Google Glass technology to help doctors more efficiently push information to most electronic health records systems and also verbally seek information from them, according to the company's website.
C.R. Bard enrolled its first patient in a new U.S. clinical trial of its drug-coated balloon. The technology could provide an alternative to traditional treatment methods for in-stent restenosis, the company said in a statement.
Ipsen announced "positive results" in a Phase II trial of Dysport in patients with urinary incontinence. That could put Ipsen's drug in line for more head-to-head competition with Allergan's Botox, which has successfully expanded into several medical uses.
Nearly three years removed from his Celgene retirement, Sol Barer is working to get another biotech off the ground, piecing together four drugmakers into a whole called RestorGenex and setting out to make a difference in dermatology, ocular diseases and women's health.
MD Anderson's popular "moon-shot" immuno-oncology research project has won over another big industry player looking to play catch-up in the hottest race in cancer drug R&D. AstraZeneca's biologics arm, MedImmune, has become the latest Big Pharma player to join a team that has already attracted Pfizer and J&J.
Three more drug developers are angling to go public in the waning days of a bustling first quarter for biotech IPOs, swinging for a combined $133 million to bankroll their programs. Agile Therapeutics, Aldeyra Therapeutics and GlobeImmune have all queued up for Wall Street debuts, hoping 2014's bull market lasts long enough to pull off offerings.
After the markets closed last night, Prosensa issued an upbeat self-assessment of its 48-week extension data from a Phase II study of its lead drug drisapersen for Duchenne muscular dystrophy.
Intercept Pharmaceuticals delivered a bad news-good news punch over the weekend about its lead drug.